‘MMS Doc’ jailed for teen girl sex attacks

A 39-year-old Norwegian doctor has been jailed for ten years for a series of rapes and sex attacks on underage female patients - attacks which he filmed on his mobile phone.

The Eidsivating court of appeal in Hamar found the doctor guilty on four counts of rape, three counts of attempted rape and for performing sexual acts with a minor. 

The doctor, commonly known in Norway as the 'MMS doctor' because of his use of his phone to film the sex acts, was found by police to have pressurized around 20 young girls into having sex with him.


The court said there was a significant risk that the doctor would offend again if he was released and that a custodial sentence was merited. The doctor's lawyer, Harald Stabell, said he was disappointed by the sentence:


"But he's not exactly surprised," he told newspaper Ø, pointing to evidence given by experts that the doctor was a paedophile and sadomasochist. He said there was a good chance that the case would be taken up by the Supreme Court.


The man was sentenced to ten years imprisonment earlier in the summer by Hedmarken district court, a sentence now upheld by the higher court.


Member comments

Log in here to leave a comment.
Become a Member to leave a comment.


Norwegian authorities reject new motor neurone disease medicine

Approval has been rejected for the use of the compound edaravone to treat motor neurone disease in Norway.

Norwegian authorities reject new motor neurone disease medicine
File photo: Thomas Winje Øijord / NTB scanpix

The medicine was assessed by the National System for Managed Introduction of New Health Technologies within the Specialist Health Service in Norway (Nye Metoder, NM) on Monday, news agency NTB reports via media Vårt Land.

“We will not be introducing edaravone as a treatment option because it has an uncertain and likely small effect,” the authority’s CEO Stig A. Slørdahl told Dagens Medicin.

Motor neurone disease, also known as amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease, is a serious disease that causes the death of neurons controlling voluntary muscles.

Many patients develop cognitive as well as physical symptoms. The cause of the disease is not fully understood.

Edaravone protects nerve cells from damage by a form of particle known as free radicals. Studies show that this can slow the progression of the disease, NTB writes.

It is yet to gain approval in Europe but has been used in the United States, Japan and South Korea.

According to the Norwegian Medicines Agency, 28 patients in Norway are currently receiving the treatment. The course of treatment is six months at a cost of one million kroner (134,000 euros) per patient.

The agency writes that only one out of three recognised medical journals, based on four various studies, concluded a positive overall effect of the drug compared to a placebo. In that conclusion, the medicine had a small effect on a subgroup of patients at an early stage of the progressive disease, NTB writes.

READ ALSO: Norwegian hepatitis C patients wait for treatment due to medicine monopoly: report